Switch theme
Sign up to access all valuation multiples
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
1974
2.1K+
LTM Revenue $503M
LTM EBITDA $33.5M
$503M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Inotiv has a last 12-month revenue (LTM) of $503M and a last 12-month EBITDA of $33.5M.
In the most recent fiscal year, Inotiv achieved revenue of $491M and an EBITDA of -$26.8M.
Inotiv expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Inotiv valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $503M | XXX | $491M | XXX | XXX | XXX |
| Gross Profit | $119M | XXX | $111M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | $33.5M | XXX | -$26.8M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -5% | XXX | XXX | XXX |
| EBIT | -$35.6M | XXX | -$54.5M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | -$66.6M | XXX | -$108M | XXX | XXX | XXX |
| Net Margin | -13% | XXX | -22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $372M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 1, 2025, Inotiv's stock price is $2.
Inotiv has current market cap of $71.1M, and EV of $503M.
See Inotiv trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $503M | $71.1M | XXX | XXX | XXX | XXX | $-2.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 1, 2025, Inotiv has market cap of $71.1M and EV of $503M.
Inotiv's trades at 1.0x EV/Revenue multiple, and -46.1x EV/EBITDA.
Equity research analysts estimate Inotiv's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inotiv has a P/E ratio of -1.1x.
See valuation multiples for Inotiv and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $71.1M | XXX | $71.1M | XXX | XXX | XXX |
| EV (current) | $503M | XXX | $503M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 15.0x | XXX | -46.1x | XXX | XXX | XXX |
| EV/EBIT | -14.2x | XXX | -10.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -72.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInotiv's last 12 month revenue growth is 5%
Inotiv's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Inotiv's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inotiv's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Inotiv and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Growth | 60% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 0% | XXX | 3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inotiv acquired XXX companies to date.
Last acquisition by Inotiv was XXXXXXXX, XXXXX XXXXX XXXXXX . Inotiv acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Inotiv founded? | Inotiv was founded in 1974. |
| Where is Inotiv headquartered? | Inotiv is headquartered in United States of America. |
| How many employees does Inotiv have? | As of today, Inotiv has 2.1K+ employees. |
| Who is the CEO of Inotiv? | Inotiv's CEO is Mr. Robert W. Leasure, Jr. |
| Is Inotiv publicy listed? | Yes, Inotiv is a public company listed on NAS. |
| What is the stock symbol of Inotiv? | Inotiv trades under NOTV ticker. |
| When did Inotiv go public? | Inotiv went public in 1997. |
| Who are competitors of Inotiv? | Similar companies to Inotiv include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Inotiv? | Inotiv's current market cap is $71.1M |
| What is the current revenue of Inotiv? | Inotiv's last 12 months revenue is $503M. |
| What is the current revenue growth of Inotiv? | Inotiv revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Inotiv? | Current revenue multiple of Inotiv is 1.0x. |
| Is Inotiv profitable? | Yes, Inotiv is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Inotiv? | Inotiv's last 12 months EBITDA is $33.5M. |
| What is Inotiv's EBITDA margin? | Inotiv's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Inotiv? | Current EBITDA multiple of Inotiv is 15.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
